Guardant Health Expands Liquid Biopsy Footprint with FDA-Approved Guardant360 Liquid CDx
Event summary
- FDA approved Guardant360® Liquid CDx, the largest FDA-approved liquid biopsy panel, on May 20, 2026.
- The new test integrates genomic and epigenomic insights, expanding the genomic footprint 100x compared to the previous version.
- Guardant360 Liquid CDx delivers results in as little as seven days and is covered by Medicare and commercial insurers for over 300 million lives.
- The test is approved as a companion diagnostic for multiple therapies in non-small cell lung cancer, colorectal cancer, and advanced breast cancer.
The big picture
The FDA approval positions Guardant Health as a leader in precision oncology, leveraging AI and multiomic data to enhance cancer treatment decisions. This expansion of liquid biopsy capabilities aligns with broader industry trends toward non-invasive, comprehensive genomic profiling. The test's broad insurance coverage suggests strong market accessibility, potentially accelerating adoption.
What we're watching
- Adoption Pace
- How quickly clinicians and insurers will integrate Guardant360 Liquid CDx into standard cancer care protocols.
- Competitive Response
- Whether competitors will accelerate development of similar multiomic liquid biopsy tests.
- Revenue Impact
- The extent to which the expanded test footprint will drive Guardant Health's top-line growth.
Related topics